Immunotech Biopharm Ltd
永泰生物製藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6978)

(1) INSIDE INFORMATION
UPDATE ON CONDITIONAL NEW DRUG APPLICATION FOR EAL® FOR THE PREVENTION OF POSTOPERATIVE RECURRENCE OF LIVER CANCER
(2) RESUMPTION OF TRADING

This announcement is made by Immunotech Biopharm Ltd (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong). Reference is made to the Company's announcement dated 31 March 2025 ("**March 2025 Announcement**") relating to the recent development of the Group's core product candidate, EAL®. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the March 2025 Announcement.

The board (the "**Board**") of directors (the "**Directors**") of the Company announces that, as previously disclosed in the March 2025 Announcement of the Company, the Company submitted the conditional new drug application of EAL® for the prevention of postoperative recurrence of liver cancer to the CDE. The Company has subsequently received a "Notice on the Rejection of the Conditional New Drug Application for EAL®" dated 27 April 2026 issued by the CDE. According to the notice, "available clinical trial data indicate that EAL® has shown a trend of benefit in an immunologically characterized population, and a confirmatory clinical trial in such population is required. In the absence of the results of a confirmatory clinical trial in the immunologically characterized population, a comprehensive benefit-risk assessment of this product cannot be conducted, and therefore the new drug application for this product cannot be approved."

Pursuant to relevant laws and regulations, this rejection notice only relates to the conditional new drug application. The Company will actively carry out the preparatory work for the subsequent confirmatory clinical study and, upon completion of the corresponding study, will resubmit the new drug application for the Group's core product candidate EAL® under the regular approval procedure.

Save as disclosed above, the Company expects that other clinical trials or the development progress of the Company's other product candidates will not be affected.

INFORMATION ON EAL®

EAL® is a multi-target cellular immunotherapy product with more than a decade of track record of clinical application in the treatment of various types of cancer. EAL® is a preparation of activated and expanded T cells originally taken from a patient's autologous peripheral blood and cultured using patented methods. The main active component of the product is CD8+ cytotoxic T cells, whose surface marker is the CD3 molecule.

ABOUT THE GROUP

The Group is a leading cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T cell immunotherapy. Since its establishment in 2006, it has focused on research and development and clinical applications of cellular immunotherapy drugs for cancers and other major diseases, by applying advanced theories in immunology, cell biology, and genetics. Its product pipeline features major classes of cellular immunotherapy products, including both non-genetically-modified and genetically-modified products, as well as both multi-target and single-target products. Its main product candidates include EAL®, the CAR-T cell series and the TCR-T cell series. To learn more about the Company, please visit www.eaal.net.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The Group cannot guarantee that the Company will be able to obtain further approval for, or ultimately market, EAL®, successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

Resumption of Trading

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 1:00 p.m. on Tuesday, 28 April 2026. The Company has applied to the Stock Exchange for the resumption of trading in its shares with effect from 9:00 a.m. on Wednesday, 29 April 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and, if in any doubt, to consult their professional advisers.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 28 April 2026

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Mr Yang Fan, Mr Wang Ruihua, Mr Wang Donghu, Mr Yang Xin, Mr Liu Rui and Mr Cao Ran as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit, Ms Peng Sujiu and Mr Zhang Guoguang as independent non-executive Directors.